Glamingo Blog

You’ve had your hormone levels tested. Everything came back normal. But your hair is still thinning at the crown, your ponytail is noticeably thinner than it was three years ago, and no one can give you a clear answer. The frustration is real — and it points to a genuine complexity in the science that most hair loss content refuses to acknowledge: hormonal hair loss in women is not a single mechanism with a single fix. It is a convergence of androgens, oestrogen, thyroid hormones, follicle sensitivity, and genetics — and understanding how they interact changes what you should actually do about it.

This is the part where most articles pivot to a clean list of causes and a tidy set of solutions. That would be dishonest. The research on female hair loss is good enough to explain why your results came back normal and your hair keeps falling out — but the science is also genuinely unsettled in places, and any content that pretends otherwise is doing you a disservice. What follows is an honest account of what we know, what we don’t, and what that means for your next steps.

What ‘hormonal hair loss’ actually means — and why the label is doing too much work

The hair growth cycle and where hormones intervene

Every strand on your head is cycling through three phases: a period of active growth (the anagen phase), a short transitional period (catagen), and a resting-and-shedding phase (telogen). At any given time, roughly 85–90% of your follicles should be in active growth, with the rest resting. Hormones don’t just influence this cycle — they actively regulate it. Thyroid hormones, dihydrotestosterone (DHT), and oestrogen all have documented mechanisms of action on follicle behaviour and how long each phase lasts. When hormonal signals shift — gradually over years or abruptly after a pregnancy or pill change — more follicles can tip into telogen simultaneously. You notice this as diffuse shedding, a thinner ponytail, or a crown that’s suddenly showing scalp where it didn’t before.

Think of your hair follicles as dimmer switches that respond to hormonal signals. In men with androgenetic alopecia, DHT acts like someone steadily turning the dimmer down until the light goes out. In women, it is less like one person controlling a single switch and more like several people adjusting different switches — oestrogen, androgens, thyroid hormones — simultaneously. The room gets dimmer not because one switch fails catastrophically, but because the combined adjustment tips the balance. And because the dimmer mechanism inside each follicle is partly set by genetics, two women with identical blood panels can end up with very different amounts of light.

Why FPHL is not simply the female version of male pattern baldness

Female pattern hair loss (FPHL) — the most common form of hair loss in women — is frequently described as the female equivalent of male androgenetic alopecia. This comparison is useful up to a point and misleading beyond it. FPHL is the most common form of alopecia in women, and it is associated with significant psychological distress and impaired social functioning — but its exact hormonal cause is still not fully established. In men, the androgen-driven pathway is clear and well-characterised. In women, the same pathway is present but less dominant, and other hormonal variables play a larger role. Calling it “female pattern baldness” implies a clean parallel that the evidence doesn’t fully support. The mechanisms overlap but they are not identical, and treating them as identical is part of why so many women end up with incomplete answers.

The hormones involved — and what each one actually does to your follicles

Androgens and DHT: the sensitivity problem nobody explains clearly

DHT — the potent androgen converted from testosterone by an enzyme called 5-alpha reductase — does play a role in female hair loss. It binds to androgen receptors in susceptible follicles and gradually shortens the anagen phase, causing follicles to miniaturise over time. But here is the part the “it’s just DHT” narrative skips: androgenetic alopecia is driven by a genetically predetermined elevated sensitivity of hair follicles to androgens — meaning circulating androgen levels alone do not determine whether a woman will lose hair. The critical variable is how reactive your follicle receptors are, and that is largely set by your genetics.

Patterned hair loss in both men and women is closely associated with alterations in androgen receptor expression — confirming that this is a receptor-level mechanism, not simply a story of “too much testosterone.” A woman with androgen levels well within the normal range can still experience significant follicle miniaturisation if her receptors are highly sensitive. This is why your blood panel looked fine. It was measuring the signal, not how loudly your follicles were hearing it.

Oestrogen: the growth-phase protector that declines with age

Oestrogen’s role in hair growth gets far less attention than androgens, which is a genuine gap in how this topic is communicated. Research hypothesises that thinning hair in women is affected by declining oestrogen levels, which causes more follicles to shift into the telogen (resting and shedding) phase. Oestrogen appears to extend the active growth phase — so when levels fall, as they do progressively through perimenopause and menopause, the ratio of resting to growing follicles shifts. Hormonal changes approaching and during menopause are associated with reduced hair diameter — visible thinning and finer strands are physiological consequences of hormonal ageing, not the result of neglecting your scalp routine.

This also explains why many women notice their hair feels different in their late 30s and 40s even when nothing dramatic has happened hormonally — the shift is gradual, not a cliff edge, but the cumulative effect on strand density and thickness is real.

Thyroid hormones: the overlooked variable that mimics androgenetic loss

Both an underactive thyroid (hypothyroidism) and an overactive one (hyperthyroidism) can cause diffuse hair shedding that looks almost identical to hormonal pattern loss. Thyroid hormones regulate the pace of the hair cycle, and when they fall out of range — even at the borderline ends of “normal” — follicles can shift prematurely into telogen. The clinical complication is that thyroid-related shedding is often reversible once the underlying thyroid function is treated, whereas androgenetic loss is not. Getting these distinguished matters enormously for what you do next. If your hair loss evaluation hasn’t included thyroid function — specifically TSH, free T3, and free T4 — it isn’t complete.

Why your blood test came back ‘normal’ but your hair keeps falling out

The difference between circulating hormone levels and follicle receptor sensitivity

Standard hormone panels measure how much of a hormone is circulating in your bloodstream at the time of the draw. What they cannot measure is how sensitively your follicle receptors respond to that hormone. These are two entirely different things — and conflating them is the source of enormous diagnostic frustration for women with hair loss.

If you’ve ever suspected your hair was reacting to a hormonal shift that your blood work didn’t show, you weren’t imagining it. A woman can have DHT levels that fall neatly within the reference range and still have follicles that are genetically programmed to respond to that level as if it were far higher. The blood panel wasn’t wrong — it just wasn’t answering the right question. The question isn’t “how much DHT is circulating?” It’s “how sensitive are this woman’s follicles to the DHT that’s there?” Current standard panels don’t answer the second question.

When normal results still warrant investigation — PCOS, insulin resistance, and co-occurring conditions

Female pattern hair loss is associated with an increased risk of polycystic ovary syndrome (PCOS), which links hair thinning to broader hormonal dysregulation rather than an isolated scalp issue. PCOS involves elevated androgens, insulin resistance, and disrupted ovulation — a hormonal environment that can drive follicle miniaturisation through multiple pathways simultaneously. Significantly, some women with PCOS present with hair loss without other obvious symptoms, meaning FPHL can occasionally be the most visible sign of an underlying endocrine pattern.

Research from the American Academy of Dermatology found that women who experience hair loss may also have other medical conditions including diabetes, acne, and hormonal disorders — positioning FPHL as a potential systemic signal worth investigating beyond the scalp. If your panel showed normal hormone levels but you also carry any PCOS-adjacent symptoms — irregular cycles, weight changes around the midsection, skin changes — that context belongs in the conversation with your doctor, even if each marker looks borderline on its own.

The life stages where hormonal shifts hit hair hardest

Post-pill shedding and hormonal contraceptive withdrawal

Hormonal contraceptives suppress ovulation, which also means they alter the hormonal environment your follicles experience daily. Some pills — those with androgenic progestins — can accelerate miniaturisation in genetically susceptible women. Others, with anti-androgenic progestins, may actively slow pattern loss while you’re taking them. The disorienting part is what happens when you stop. Withdrawal from the contraceptive — regardless of which type you were on — can trigger a shedding episode called telogen effluvium, where the follicle cycle, disrupted by the abrupt hormonal shift, tips a large number of follicles into the resting phase simultaneously. The shedding typically peaks two to four months after stopping the pill, which makes it easy to misattribute to something else entirely happening in your life at that time.

The experience of hair changing unpredictably with different hormonal contraceptives is genuinely common — and it reflects exactly what the research confirms: the same hormonal change affects different women’s follicles differently, depending on their receptor sensitivity and genetic baseline.

Postpartum: the telogen effluvium that feels like a different kind of loss

During pregnancy, elevated oestrogen prolongs the anagen phase significantly — many women notice their hair looking thicker and shinier than ever. Then oestrogen levels drop sharply after delivery, and the follicles that had been held in extended growth phase all shift into telogen together. The resulting shedding, typically appearing two to four months postpartum, can be alarming in volume. Handfuls in the shower, clumps on the pillow. The reassuring part: this is almost always telogen effluvium, not permanent pattern loss, and most women see regrowth within six to twelve months.

The less reassuring part: in women who are already genetically predisposed to FPHL, postpartum can sometimes unmask an underlying pattern loss that was previously suppressed by pregnancy hormones. The shedding doesn’t fully resolve as expected, or the regrowth comes back finer. Knowing the distinction matters for deciding whether to wait it out or investigate further.

Perimenopause and menopause: why the crown thins and the hairline shifts

The thinning that arrives in the mid-to-late 40s often surprises women who have had no prior hair concerns. The mechanism is the convergence described earlier — declining oestrogen reduces the growth-phase protection follicles had, while androgen sensitivity that was previously offset becomes more apparent. The result tends to present as diffuse thinning at the crown and a widening part, rather than the receding hairline pattern more typical in men. Hormonal changes approaching and during menopause are associated with reduced hair strand diameter, meaning the individual hairs that do grow become finer, compounding the visual effect of reduced density. This is not about neglect or the wrong shampoo. It is a predictable consequence of hormonal ageing — which also means it can be addressed with hormonal context in mind.

What the evidence actually supports for treatment — and what it does not

Minoxidil: the only topical with solid evidence, and what it does not fix

Minoxidil is the most evidence-supported topical treatment for FPHL. It works by extending the anagen phase and improving blood flow to the follicle — it does not block androgens or address receptor sensitivity. This means it manages the condition rather than treating the underlying hormonal cause. It also requires ongoing use to maintain results; stopping it typically leads to a return to the prior trajectory. The 2% and 5% formulations are both used in women, with the 5% showing somewhat better response in some studies, though with a higher rate of facial hair growth as a side effect. For women in Singapore’s humidity, the foam formulation tends to be better tolerated than the solution during warmer months.

Anti-androgen approaches: the evidence grade for spironolactone and finasteride in women

Spironolactone, an anti-androgen medication originally developed as a blood pressure treatment, blocks androgen receptors and reduces DHT’s effect on follicles. It is used off-label for FPHL in women, particularly those with signs of hormonal excess or PCOS, and has a reasonable evidence base for slowing progression and improving density in appropriate candidates. It is not suitable during pregnancy and requires monitoring. Finasteride, which inhibits 5-alpha reductase to reduce DHT production, has strong evidence in men and more limited but growing evidence in postmenopausal women. One review found that 88% of women either experienced improvement or had no progression of hair loss with available hormonal treatment approaches — though this finding covers a range of treatments and follow-up durations and should be understood as directionally encouraging rather than a guaranteed outcome. Both medications require a prescribing doctor and individual assessment; neither is a first-line self-treatment.

What ‘lifestyle-based’ approaches can and cannot do hormonally

Nutrition, stress management, sleep, and scalp care are not irrelevant — chronic stress elevates cortisol, which can disrupt the hormonal balance that regulates follicle cycling; iron deficiency and protein insufficiency genuinely impair hair growth; and scalp inflammation creates a microenvironment that compounds follicle miniaturisation. These are real variables. What they are not is a substitute for addressing the underlying hormonal mechanism in women with genuine FPHL. Managing insulin resistance through dietary changes can have meaningful hormonal downstream effects for women with PCOS-related hair loss. But no supplement, scalp massage protocol, or haircare product directly addresses androgen receptor sensitivity. Be specific about what you’re treating and realistic about what any given intervention can reach.

The psychological weight of hair loss in women — and why it keeps getting minimised

A systematic review of qualitative studies found that alopecia results in multiple psychosocial consequences affecting identity and appearance, with women experiencing these impacts at clinically meaningful levels. Hair in many cultures — including across Singapore’s Chinese, Malay, and Indian communities — carries layered meaning around femininity, health, and social presentation. The grief of watching it thin is not vanity. It is a legitimate response to a visible change that touches identity in ways that are not straightforwardly reversible.

And yet the dismissal women encounter — “your levels are normal,” “it’s just stress,” “it’s part of ageing” — is itself measurably harmful. Being told your concern isn’t real when you can see it in the mirror every morning does damage beyond the hair loss itself. The psychological impact of FPHL is disproportionately severe compared to men, partly because hair loss in women carries stronger social stigma, and partly because women are more likely to face diagnostic minimisation in clinical settings. Name this when you encounter it. The evidence is on your side.

What to actually do next: how to build a case before your next clinic visit

Arriving at a GP or dermatologist with “my hair has been falling out” and a blood panel that says normal leaves you vulnerable to being sent away with nothing actionable. Arriving with a documented timeline and specific contextual questions is a different conversation entirely.

A useful pre-appointment workup includes documenting the pattern of loss — crown, diffuse, hairline — and photographing it consistently in the same lighting over time. Ask specifically about thyroid function (TSH, free T3, free T4), ferritin (not just haemoglobin — ferritin can be low while full blood count looks normal), DHEA-S and free androgen index if PCOS is a possibility, and oestradiol if you are in your 40s and experiencing other perimenopause signals. A trichologist can provide a scalp assessment and hair density count that gives you objective baseline data independent of blood results.

Most importantly: the hormonal events in your history are diagnostic data. They don’t show up on a blood panel. They live in your memory — and writing them down turns them into clinical evidence.

Before your next clinic or trichologist appointment, write down the timeline of any hormonal events in the past two to three years — starting or stopping contraceptives, postpartum recovery, any PCOS diagnosis or symptoms, perimenopause signs — alongside when you first noticed the shedding or thinning. This timeline is the diagnostic context a blood panel alone cannot provide, and it is the difference between a doctor dismissing your ‘normal results’ and actually investigating the right variables.

If you’re ready to get a professional scalp and hair assessment rather than navigating this alone, Glamingo lists verified trichologists and hair loss clinics across Singapore with real reviews from women who’ve been through the same diagnostic maze. Find a trichologist near you →